Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 6/20 | 0.66 |
| ▸ | EDNRB | P24530 | 4/20 | 0.66 |
| ▸ | DHPS | P49366 | 14/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.57 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7793953 | 0.98 | EDNRA (0.64) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL2490097 | 0.96 | EDNRA (0.62) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL2491102 | 0.93 | EDNRA (0.59) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL2487364 | 0.92 | EDNRA (0.59) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| Phenetole SCHEMBL2489884 | 0.92 | EDNRA (0.58) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL3828250 | 0.91 | EDNRA (0.63) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL2493351 | 0.91 | EDNRA (0.57) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL2489882 | 0.90 | EDNRA (0.56) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL8007885 | 0.90 | EDNRA (0.55) | EDNRAEDNRBDHPSABCC3ABCC4 | |
| SCHEMBL7787027 | 0.89 | EDNRA (0.53) | EDNRAEDNRBDHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072503-A2 | Process for the preparation of bosentan | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | claimed |
| US-20090156811-A1 | Process for the Preparation of Bosentan | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-18 | — | — | US | claimed |
| WO-2012056468-A1 | A PROCESS FOR THE PREPARATION OF BOSENTAN | MATRIX LABORATORIES LTD (IN) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012056468-A1 | A PROCESS FOR THE PREPARATION OF BOSENTAN | MATRIX LABORATORIES LTD (IN) | 2012-05-03 | — | — | WO | disclosed |
| EP-2072503-B1 | Process for the preparation of bosentan | DIPHARMA FRANCIS SRL (IT) | 2011-10-26 | — | — | EP | disclosed |
| EP-2268634-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | Actavis Group PTC EHF (IS) | 2011-01-05 | — | — | EP | disclosed |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | GLENMARK (IN) | 2010-10-07 | — | — | US | disclosed |
| WO-2009112954-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2009-09-17 | — | — | WO | disclosed |
| EP-2072503-A2 | Process for the preparation of bosentan | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156811-A1 | Process for the Preparation of Bosentan | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-0959072-B1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0959072-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| US-5739333-A | 4-SULFONAMIDO-6-ARYLOXY OR -AMINOALKYLENEOXY,-AMINO, OR -THIOPYRIMIDINES; ENDOLTHELIN ANTAGONISTS; HYPOTENSIVE AND ULCER AGENTS; ASTHMA; RAYNAUD DISEASE; CARDIOVASCULAR DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0743307-A1 | Sulfonamide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1996-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | PTGIS, EDNRB, CYP11B2 | EDNRA 6/4885EDNRB 2/4885DHPS 30/4885 |
| US-20090156811-A1 | Process for the Preparation of Bosentan | PAH, HBB, HBZ | EDNRA 32/4885EDNRB 8/4885DHPS 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.